Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epstein-Barr virus vaccines.

A J Morgan1

  • 1Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, UK.

Vaccine
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Epstein-Barr virus (EBV) infects most people worldwide and is linked to cancers like Burkitt's lymphoma and nasopharyngeal carcinoma. Vaccines targeting the EBV glycoprotein gp340 are in development to prevent these serious diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effectiveness of an Australian community suicide prevention networks program in preventing suicide: a controlled longitudinal study.

BMC public health·2022
Same author

Lessons learnt from the field: a qualitative evaluation of adolescent experiences of a universal mental health education program.

Health education research·2020
Same author

Severe community-acquired pneumonia.

BJA education·2020
Same author

Effect of community members' willingness to disclose a mental disorder on their psychiatric symptom scores: analysis of data from two randomised controlled trials of mental health first aid training.

Epidemiology and psychiatric sciences·2019
Same author

The distribution of cadmium, copper, lead, zinc and calcium in the tissues of the earthworm Lumbricus rubellus sampled from one uncontaminated and four polluted soils.

Oecologia·2017
Same author

Disclosure of mental health problems: findings from an Australian national survey.

Epidemiology and psychiatric sciences·2017
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Area of Science:

  • Virology
  • Oncology
  • Immunology

Background:

  • Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus, infecting over 95% of the global population.
  • While typically asymptomatic or causing mild illness, EBV is associated with significant diseases, including endemic Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), infectious mononucleosis, and certain cancers in immunosuppressed individuals.
  • EBV's association with Hodgkin's disease, a common Western cancer, has also been recently established.

Purpose of the Study:

  • To review the significance of Epstein-Barr virus (EBV) infections and associated diseases.
  • To discuss the development and potential of vaccines targeting EBV, particularly the gp340 envelope glycoprotein.
  • To highlight the role of EBV vaccines in preventing EBV-related cancers and other pathologies.

Related Experiment Videos

Main Methods:

  • Review of epidemiological data on EBV prevalence and associated diseases.
  • Analysis of vaccine development strategies focusing on EBV envelope glycoprotein gp340.
  • Examination of ongoing clinical trials for EBV vaccines, including recombinant viral vectors and subunit vaccines.

Main Results:

  • EBV is a major global health concern due to its high prevalence and association with specific cancers (BL, NPC) and conditions like infectious mononucleosis.
  • Vaccines based on the EBV gp340 glycoprotein show promise for reducing or eliminating EBV-associated endemic cancers.
  • Novel vaccine platforms, including recombinant vaccinia, varicella, adenovirus vectors, and subunit vaccines, are advancing towards human trials.

Conclusions:

  • EBV poses a significant global health challenge, necessitating effective prevention strategies.
  • Vaccination against EBV, specifically targeting gp340, offers a promising approach to control EBV-related malignancies, particularly in high-risk populations.
  • The development of safe and effective EBV vaccines holds potential for disease prevention in both endemic and Western populations, including those with compromised immunity.